What is the safety and efficacy of IV glycoprotein IIb/IIIa inhibitors administered during endovascular stroke treatment?
The safety and efficacy of IV glycoprotein IIb/IIIa inhibitors administered during endovascular stroke treatment is uncertain. This is based on the published literature which is limited primarily to case series and retrospective reviews of single-center databases and focuses largely on administration of IV glycoprotein IIb/IIIa inhibitors to prevent thrombus formation during emergent carotid and vertebrobasilar artery stenting. Further research is needed comprising multicenter analyses of endovascular stroke therapy necessitating adjunctive antiplatelet therapy for emergent angioplasty and stenting.